UNSPSC 51282136: Pivampicillin pamoate

This classification denotes a penicillin antibiotic with the molecular formula C23H16O6.2C22H29N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z5TRG74EY, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (2s-((2 alpha, 5 alpha, 6 beta(s*))))-, 4,4-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (2:1) but more generally known as pivampicillin pamoate, which bears US NIH Compound Identifier 3084732.

UNSPSC 51282136 Pivampicillin pamoate is a Commodity code for a specific antibiotic pharmaceutical product, yet the recent state and local opportunities posted under this code do not reflect procurement of pivampicillin pamoate itself. Instead, the tagged solicitations document purchases of unrelated pharmaceutical products and medical supplies — including doxycycline hyclate, ciprofloxacin hydrochloride, naloxone, and drug deactivation systems — suggesting a mismatch between the code assignment and the work actually being bought. State and local procurement offices appear to use this code as a general pharmaceutical or medical-supply catch-all rather than as a narrow product identifier. When state and local governments do solicit under this code, they are acquiring finished pharmaceutical inventory for public health and emergency response programs, typically through piggyback cooperative purchasing vehicles or competitive ITB processes with multi-year contract terms and quarterly or as-needed delivery schedules.

The issuing bodies include state health departments and county government purchasing offices. Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392, ITB, $2,999,999.11 over three years with renewal options), while Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term. Activity appears concentrated in Florida and Illinois, though the code assignment suggests broader pharmaceutical purchasing intent. Vendors pursuing opportunities under this code should verify the actual commodities required in each solicitation rather than assuming pivampicillin pamoate specificity, and should be prepared to manage cooperative purchasing frameworks, multi-year delivery schedules, and state-level pharmaceutical compliance requirements including drug-free workplace certification and E-Verify compliance.